SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
The SLS009 aza-ven treatment was well-tolerated and evoked anti-leukemic effects in 67% of patients across all levels dosed.
- The SLS009 aza-ven treatment was well-tolerated and evoked anti-leukemic effects in 67% of patients across all levels dosed.
- The first patient who achieved a complete response continues on the study and remains leukemia-free 9 months post-enrollment.
- The net proceeds from the offering strengthen the Company’s financial position and will be used for research and development activities, working capital, and general corporate purposes.
- Cash Position: As of December 31, 2023, cash and cash equivalents totaled approximately $2.5 million.